MedTrace Logo

European Alpha-Mannosidosis Participant

NCT03651245 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 667

Last updated 2022-06-13

No results posted yet for this study

Summary

International, multicenter, observational, longitudinal monitoring study to investigate the prevalence of Alpha-Mannosidosis in participants at risk for Alpha-Mannosidosis.

Conditions

  • Immunodeficiency
  • Skeletal Abnormalities
  • Deafness
  • Mental Retardation
  • Gingival Hypertrophy
  • Facial Dysmorphism

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. Dr. · CENTOGENE GmbH

Eligibility

Min Age
2 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-05-30
Completion
2022-05-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651245 on ClinicalTrials.gov